UNIGE document Scientific Article - Case report
previous document  unige:122879  next document
add to browser collection

Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient

Breville, Gauthier
Published in Multiple sclerosis and related disorders. 2019, vol. 34, p. 63-65
Abstract Fingolimod is the first approved oral disease-modifying treatment for relapsing-remitting multiple sclerosis. Fingolimod targets lymphocytes, exerting a modulator effect on cell-surface sphingosine-1-phosphate receptors and thus blocking lymphocytes egression from secondary lymphoid organs. Recent reports describe fingolimod cessation being followed by severe or pseudo-tumoral relapse, but it usually does not happen on continuous long-term treatment.
PMID: 31229736
Full text
Article (Published version) (687 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups La Sclérose en plaques (908)
Scléroses en plaques, neuroimmunologie, encéphalite autoimmune expérimentale (843)
(ISO format)
BREVILLE, Gauthier et al. Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient. In: Multiple Sclerosis and Related Disorders, 2019, vol. 34, p. 63-65. doi: 10.1016/j.msard.2019.06.017 https://archive-ouverte.unige.ch/unige:122879

274 hits



Deposited on : 2019-09-09

Export document
Format :
Citation style :